Clinical trials: Cystic Fibrosis Related Diabetes
Cystic Fibrosis Related Diabetes, Cystic Fibrosis
Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)
This study is aimed at better understanding the impact of ivacaftor upon insulin and incretin secretion and glucose tolerance in patients with Cystic Fibrosis with a glycine (G551D) mutation.
- Trial name
- NCT02039986
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Children's Hospital of Philadelphia
Cystic Fibrosis
Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis
Cystic fibrosis (CF)-related diabetes (CFRD) is the most important emerging complication after pulmonary complications. This specific form of diabetes is associated with an increased morbidity and mortality.
- Trial name
- ProspeC-F (NCT05099939)
- Where
- 4 sites in Canada, France
- Volunteers
- 121 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis-related Diabetes
Bionic Pancreas in CFRD
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin…
- Trial name
- NCT06449677
- Testing
- iLet Bionic Pancreas System (BP), Usual Care (UC)
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Jaeb Center for Health Research
Cystic Fibrosis, Cystic Fibrosis Related Diabetes
Effects of an Exercise Program Among CF Patients With Dysglycemia
The objective of the investigators research program is to determine whether a combined exercise program (aerobic and resistance) improves abnormal glucose tolerance and diabetes control in CF patients.
- Trial name
- FKEX (NCT02127957)
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis-related Diabetes
Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes
Cystic fibrosis related diabetes (CFRD) is a major factor of morbidity and mortality at all disease stages. Insulin deficiency has serious clinical consequences by increasing malnutrition, since protein and lipid catabolism is…
- Trial name
- MIRE (NCT04381429)
- Testing
- A-F-A-F (NovoRapid-FIASP-NovoRapid-FIASP), F-A-F-A (FIASP-NovoRapid-FIASP-NovoRapid)
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Strasbourg, France
Cystic Fibrosis
Sitagliptin in Cystic Fibrosis-Related Diabetes
The purpose of this study is to determine whether the dipeptidyl peptidase IV (DPPIV) inhibitor sitagliptin is effective in the treatment of cystic fibrosis-related diabetes (CFRD).
- Trial name
- NCT01257464
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of British Columbia
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis
With improved survival, the clinical spectrum of cystic fibrosis (CF), a complex multi systemic disease, continue to evolve. A major emerging complication is CF related diabetes (CFRD) which is occurring in 40-50% of adults.
- Trial name
- SOFI (NCT02810691)
- Testing
- Soluble fiber supplementation
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes, Cystic Fibrosis
Training in Shared Decision-making of Cystic Fibrosis Centers Competences in the Treatment of CF Related Diabetes in Adult Patients
Diabetes affects half of cystic fibrosis patients aged 30 years and older. It develops asymptomatically for a long time. Also, two options are possible: start insulin treatment now with the additional constraints associated with…
- Trial name
- FORAIDMUCO (NCT04891159)
- Testing
- Shared decision making
- Where
- 4 sites in France
- Volunteers
- 40 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis, Pancreatic Insufficiency
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
Diabetes is a major co-morbidity in pancreatic insufficient cystic fibrosis (PI-CF) and associated with worse outcomes. While reduced β-cell mass contributes to the insulin secretory defects that characterizes cystic…
- Conditions
- Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
- Trial name
- NCT04731272
- Testing
- Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Pancreatic Insufficiency, Cystic Fibrosis-related Diabetes
Dorzagliatin in Pancreatic Insufficient Cystic Fibrosis
This study is designed to determine the pharmacokinetic and pharmacodynamic response of dorzagliatin 50 mg twice daily following 7-day administration in individuals with pancreatic insufficient cystic fibrosis and abnormal…
- Trial name
- NCT06995651
- Testing
- Dorzagliatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Michael R. Rickels, MD, MS
Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
A CFit Study - Baseline
A great medical success is the increase in the median survival age associated with cystic fibrosis (CF). However, this success has led to a new era of research with the aim to maximise the quality of life (QoL) of the aging CF…
- Trial name
- NCT03234387
- Testing
- No intervention - only assessments.
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Portsmouth
Cystic Fibrosis Related Diabetes
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR…
- Trial name
- NCT07102043
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis
Development of Diabetes in Adults With Cystic Fibrosis (CF)
This is a crossover study to determine the possible factors that might be related to the development of diabetes in CF and examines the relationship between pancreatic fatigue if any, and the development of diabetes.
- Trial name
- CF-DIABETES (NCT03644199)
- Testing
- Oral Glucose Tolerance Test (OGTT) assessment arm, Mixed meal test evaluation test arm
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Liverpool Heart and Chest Hospital NHS Foundation Trust
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF)
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
The investigators are conducting a pilot open-label pre/post interventional trial in adolescents and adults with cystic fibrosis (CF) and abnormal glucose tolerance or early CF-related diabetes mellitus (CFRD) to assess the…
- Conditions
- Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
- Trial name
- NCT07688070
- Testing
- Verapamil Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rhode Island Hospital
Cystic Fibrosis-related Diabetes
Closed-loop for People Living With Cystic Fibrosis Related Diabetes
The main objective of this study is to determine whether closed-loop glucose control is superior to standard insulin therapy with continuous glucose monitoring (CGM) in young people (≥16 years) and adults with cystic fibrosis…
- Trial name
- CL4P-CF (NCT05562492)
- Testing
- CamAPS FX, Standard insulin therapy with CGM
- Where
- 14 sites in United Kingdom
- Volunteers
- 128 people
- Sponsor
- University of Cambridge
Cystic Fibrosis-related Diabetes
Feasibility of Outpatient Closed Loop Control With the iLet Bionic Pancreas in Cystic Fibrosis Related Diabetes
The current study is designed to test the feasibility of the a wearable bionic pancreas system that automatically delivers insulin and glucagon can provide superior regulation of glycemia versus usual care for adults and children…
- Trial name
- NCT03258853
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Massachusetts General Hospital
Cystic Fibrosis
Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients
YKL-40 is proposed as a biomarker of various inflammatory disease diabetes and lung disease including cystic fibrosis. In those cross-sectional studies, a unique value of YKL-40 is used to correlate with clinical, physiological…
- Trial name
- Kin_YKL_CF (NCT02305784)
- Where
- Canada
- Volunteers
- 188 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
This will be a placebo-controlled, randomized, double blind, crossover study with a 4 week wash out period. Collect pilot data on the safety, tolerability, and feasibility of empagliflozin therapy in overweight/obese patients…
- Trial name
- NCT06149793
- Testing
- Empagliflozin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
A CFit Study - Acute Exercise
A great medical success is the increase in the median survival age associated with cystic fibrosis (CF). However, this success has led to a new era of research aiming to maximise the quality of life (QoL) of the aging CF…
- Trial name
- NCT03237767
- Testing
- MIE, HIIE
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- University of Portsmouth
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function
The purpose of this study is to assess the efficacy of metformin to improve airway ion channel function in those with CF-related diabetes (CFRD)
- Trial name
- NCT04530383
- Testing
- Metformin Hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center